---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-097741"
form_type: "8-K/A"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:52:32.221081+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nkarta Q2 net loss $25M; cash $426.7M; NKX019 autoimmune trial Ntrust-2 to start by year-end

## Summary
- Net loss of $25.0M ($0.34 diluted EPS); R&D expense $23.1M, G&A $7.6M.
- Cash & investments $426.7M expected to fund operations into late 2027.
- FDA cleared second IND for NKX019 in autoimmune disease; Ntrust-2 enrollment for systemic sclerosis, myositis, vasculitis expected by year-end 2024.
- Preliminary Ntrust-1 and Ntrust-2 data planned for 2025; NHL 7-day dosing cohort enrollment completed, data due late 2024.
- Nadir Mahmood joined as President; David Shook promoted to CMO, Head of R&D.

## SEC filing metadata
- accession: 0000950170-24-097741
- form_type: 8-K/A
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017024097741/0000950170-24-097741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017024097741/nktx-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-097741
- JSON: https://secwatch.observer/filing/0000950170-24-097741.json
- Plain text: https://secwatch.observer/filing/0000950170-24-097741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.